睿知中国疾病研究地图
候选清单0

济南山东大学

山东大学第二医院

Second Hospital of Shandong University

在本站收录的 53 种疾病中,这家医院列在其中 13 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

山东大学第二医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 食管鳞状细胞癌Oesophageal squamous cell carcinoma10 篇牵头论文牵头 1 项开放试验
  2. 肝细胞癌Hepatocellular carcinoma41 篇牵头论文
  3. 胃癌Stomach cancer22 篇牵头论文牵头 1 项开放试验
  4. 骨肉瘤Osteosarcoma14 篇牵头论文
  5. 神经母细胞瘤Neuroblastoma1 篇牵头论文
  6. 多发性骨髓瘤Multiple myeloma7 篇牵头论文
  7. 再生障碍性贫血Aplastic anaemia2 篇牵头论文
  8. 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder2 篇牵头论文
  9. 重症肌无力Myasthenia gravis2 篇牵头论文
  10. 特发性肺纤维化Idiopathic pulmonary fibrosis3 篇牵头论文
  11. 杜氏肌营养不良Duchenne muscular dystrophy1 篇牵头论文
  12. IgA 肾病IgA nephropathy1 篇牵头论文
  13. 原发性胆汁性胆管炎Primary biliary cholangitis0 篇牵头论文

未列出的收录疾病:鼻咽癌、肝母细胞瘤、视网膜母细胞瘤、脊索瘤、胃肠道间质瘤、尤文肉瘤、B 细胞急性淋巴细胞白血病、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、IgG4相关性疾病、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、白塞病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 10 篇,占 0.3%。

牵头论文
10
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 4420232024: 2220242025: 112025

济南有 6 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma
    分期
    不分期
    开始
    2024-12
    登记号
    NCT07430579

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:山东大学第二医院;另有 1 家列出的医院为研究中心济南

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题分子标志物与基因新辅助与综合治疗

这些论文过半是实验室或动物研究。

牵头的论文10
  1. Disulfiram impairs USP21-mediated MOF-K257 deubiquitination to inhibit esophageal squamous cell carcinoma progression.2025Cancer letters
  2. miR-493-5p Silenced by DNA Methylation Promotes Angiogenesis via Exosomes and VEGF-A-Mediated Intracellular Cross-Talk Between ESCC Cells and HUVECs.2024International journal of nanomedicine免费全文
  3. Stabilization of MOF (KAT8) by USP10 promotes esophageal squamous cell carcinoma proliferation and metastasis through epigenetic activation of ANXA2/Wnt signaling.2024Oncogene
  4. The Function of lncRNA LINC00997 as a Diagnostic Marker in the Progression of Esophageal Squamous Cell Carcinoma.2023Annals of clinical and laboratory science
  5. Circular RNA circ-FIRRE interacts with HNRNPC to promote esophageal squamous cell carcinoma progression by stabilizing GLI2 mRNA.2023Cancer science免费全文
  6. CircABCA13 acts as a miR-4429 sponge to facilitate esophageal squamous cell carcinoma development by stabilizing SRXN1.2023Cancer science免费全文
  7. Exosomal miR-10527-5p Inhibits Migration, Invasion, Lymphangiogenesis and Lymphatic Metastasis by Affecting Wnt/β-Catenin Signaling via Rab10 in Esophageal Squamous Cell Carcinoma.2023International journal of nanomedicine免费全文
  8. USP36 facilitates esophageal squamous carcinoma progression via stabilizing YAP.2022Cell death & disease免费全文
  9. Construction and Evaluation of a Risk Score Model for Lymph Node Metastasis-Associated Circadian Clock Genes in Esophageal Squamous Carcinoma.2022Cells免费全文
  10. A network meta-analysis for neoadjuvant and adjuvant treatments for resectable squamous cell carcinoma of esophagus.2021Scientific reports免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma正在招募NCT07430579牵头方不分期2024-12 启动
PubMed 以外找到的论文(未计入)3
  1. 103P Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter, prospective, single-arm, real-world study2024Immuno-Oncology Technology论文
  2. Abstract 6847: IGF2BP3 promotes esophageal squamous cell carcinoma progressions via Wnt/CTNNB1 pathway2024Cancer Research会议摘要
  3. Construction of a survival model for Esophageal Squamous Carcinoma and prediction of potential treatment with herbal medicine2023Research Square预印本

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 41 篇,占 0.3%。

牵头论文
41
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 8820212022: 5520222023: 151520232024: 7720242025: 662025

济南有 6 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝细胞癌开放试验。

这些数字背后的记录
研究主题乙肝与肝硬化免疫与靶向药物复发与预后
论文中的科室普外/肝胆胰外科病理/检验科消化/肝病科影像/核医学科
牵头的论文41
  1. Efficacy and Safety of HAIC-FOLFOX Plus Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-line Treatment for Unresectable Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.2025Academic radiology
  2. Nonlinear relationship between age and the risk of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis.2025BMC infectious diseases免费全文
  3. Identification of anoikis-related subtypes and a risk score prognosis model, the association with TME landscapes and therapeutic responses in hepatocellular carcinoma.2025Frontiers in immunology免费全文
  4. Epigenetic modulation with nanosatellite triggers tumoricidal immunity for hepatocellular carcinoma treatment.2025Nature communications免费全文
  5. Ginsenoside Rb prevents the metastasis of hepatocarcinoma by blocking the platelet-tumor cell interaction.2025Naunyn-Schmiedeberg's archives of pharmacology
  6. Phthalate exposure and hepatocellular carcinoma: Unraveling mechanisms through network toxicology.2025Toxicology
  7. The double roles of T cell-mediated immune response in the progression of MASLD.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  8. The efficacy of sorafenib against hepatocellular carcinoma is enhanced by 5-aza-mediated inhibition of ID1 promoter methylation.2024FEBS open bio免费全文
  9. Attenuation of pro-tumorigenic senescent secretory phenotype by StN, a novel derivative of stevioside, potentiates its inhibitory activity on hepatocellular carcinoma.2024Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  10. Risk of HCC decreases in HBV-related patients with cirrhosis acquired recompensation: A retrospective study based on Baveno VII criteria.2024Hepatology communications免费全文
  11. HBV DNA polymerase regulates tumor cell glycogen to enhance the malignancy of HCC cells.2024Hepatology communications免费全文
  12. HBV DNA polymerase upregulates the transcription of PD-L1 and suppresses T cell activity in hepatocellular carcinoma.2024Journal of translational medicine免费全文
  13. Elevated Hepatitis B virus RNA levels in hepatocellular carcinoma patients compared to cirrhotic individuals: A propensity score matched analysis.2024Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association免费全文
  14. Epirubicin may enhance the inhibition of hepatocellular carcinoma induced by iodine-125 seeds through downregulating WNT pathway.2023Asia-Pacific journal of clinical oncology
  15. IL-8-induced CXCR2 down-regulation in circulating monocytes in hepatocellular carcinoma is partially dependent on MAGL.2023BMC cancer免费全文
  16. From NAFLD to HCC: Advances in noninvasive diagnosis.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  17. Efficacy and safety of immune checkpoint inhibitors for hepatocellular carcinoma patients with macrovascular invasion or extrahepatic spread: a systematic review and meta-analysis of 54 studies with 6187 hepatocellular carcinoma patients.2023Cancer immunology, immunotherapy : CII免费全文
  18. MELK promotes HCC carcinogenesis through modulating cuproptosis-related gene DLAT-mediated mitochondrial function.2023Cell death & disease免费全文
  19. USP1 modulates hepatocellular carcinoma progression via the Hippo/TAZ axis.2023Cell death & disease免费全文
  20. Adverse events of immune checkpoint inhibitors in hepatocellular carcinoma: a systemic review and meta-analysis.2023Clinical and experimental medicine
  21. Bronchial artery chemoembolization with drug-eluting beads versus bronchial artery infusion followed by polyvinyl alcohol particles embolization for advanced squamous cell lung cancer: A retrospective study.2023European journal of radiology
  22. Early alpha-fetoprotein response predicts prognosis of immune checkpoint inhibitor and targeted therapy for hepatocellular carcinoma: a systematic review with meta-analysis.2023Expert review of gastroenterology & hepatology
  23. Decreased granzyme-B expression in CD11c+CD8+ T cells associated with disease progression in patients with HBV-related hepatocellular carcinoma.2023Frontiers in immunology免费全文
  24. Silencing lncRNA HCG18 regulates GPX4-inhibited ferroptosis by adsorbing miR-450b-5p to avert sorafenib resistance in hepatocellular carcinoma.2023Human & experimental toxicology
  25. Evaluating liver function and the impact of immune checkpoint inhibitors in the prognosis of hepatocellular carcinoma patients: A systemic review and meta-analysis.2023International immunopharmacology
  26. The Association of Glycemic Index, Glycemic Load, and Daily Carbohydrates Intake with the Risk of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.2023Nutrition and cancer
  27. Perfusion parameters of triphasic computed tomography hold preoperative prediction value for microvascular invasion in hepatocellular carcinoma.2023Scientific reports免费全文
  28. Identification of Hub Genes and Immune Infiltration in Non-alcoholic Fatty Liver Disease -Related Hepatocellular Carcinoma by Bioinformatics Analysis.2023The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology免费全文
  29. Drug-eluting bead transarterial chemoembolization with medium-sized versus small-sized CalliSpheres microspheres in unresectable primary liver cancer.2022Asia-Pacific journal of clinical oncology免费全文
  30. Loss of WNK1 Suppressed the Malignant Behaviors of Hepatocellular Carcinoma Cells by Promoting Autophagy and Activating AMPK Pathway.2022Disease markers免费全文
  31. The causal relationship between white blood cell counts and hepatocellular carcinoma: a Mendelian randomization study.2022European journal of medical research免费全文
  32. Involvement of NF-κB/PI3K/AKT signaling pathway in the protective effect of prunetin against a diethylnitrosamine induced hepatocellular carcinogenesis in rats.2022Journal of biochemical and molecular toxicology
  33. Identification and validation of the necroptosis-related gene signature related to prognosis and tumor immune in hepatocellular carcinoma.2022Medicine免费全文
  34. USP48 Is Upregulated by Mettl14 to Attenuate Hepatocellular Carcinoma via Regulating SIRT6 Stabilization.2021Cancer research
  35. HDAC11 Regulates Glycolysis through the LKB1/AMPK Signaling Pathway to Maintain Hepatocellular Carcinoma Stemness.2021Cancer research
  36. lncRNA RBM5-AS1 promotes cell proliferation and invasion by epigenetically silencing miR-132/212 in hepatocellular carcinoma cells.2021Cell biology international
  37. Value of perfusion parameters and histogram analysis of triphasic computed tomography in pre-operative prediction of histological grade of hepatocellular carcinoma.2021Chinese medical journal免费全文
  38. Therapeutic efficacy of TACE 125I seed implantation and its combination with intra-tumor injection of cisplatin for the treatment of hepatocellular carcinoma.2021Indian journal of cancer
  39. Trans-jugular intrahepatic portosystemic shunt in patients with hepatic cellular carcinoma: A preliminary study.2021Journal of cancer research and therapeutics
  40. Higher Liver Stiffness Predicting Adverse Outcomes in Cirrhotic Patients with Child-Pugh Grades A and B.2021Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  41. Value of perfusion parameters histogram analysis of triphasic CT in differentiating intrahepatic mass forming cholangiocarcinoma from hepatocellular carcinoma.2021Scientific reports免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation状态不明NCT03356236研究中心2018-04 启动
  2. Prospective Surveillance for Very Early Hepatocellular Carcinoma状态不明NCT03588442研究中心2018-07 启动
  3. Microwave Ablation Combined With TACE in the Treatment of Unresectable Huge Hepatocellular Carcinoma Huge状态不明NCT03277716研究中心不分期2017-12 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 22 篇,占 0.2%。

牵头论文
22
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 5520222023: 8820232024: 0020242025: 662025

济南有 8 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer
    分期
    不分期
    开始
    2020-07
    登记号
    NCT04688801

    年龄 25 岁 至 80 岁(登记的条件)

    牵头:山东大学第二医院济南

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题免疫与靶向药物影像与人工智能腹膜转移与晚期
论文中的科室消化/肝病科普外/肝胆胰外科病理/检验科儿科

这些论文过半是实验室或动物研究。

牵头的论文22
  1. Nanoparticle-Mediated CXCL12-CXCR4 Inhibition Reprograms Macrophages and Suppresses Gastric Carcinoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  2. Machine learning-based integration develops a disulfidptosis-related lncRNA signature for improving outcomes in gastric cancer.2025Artificial cells, nanomedicine, and biotechnology
  3. Defining gastric cancer ecology: the crucial roles of TREM2+ macrophages and fibroblasts in tumor microenvironments.2025Communications biology免费全文
  4. The regulatory role of integrin in gastric cancer tumor microenvironment and drug resistance.2025Progress in biophysics and molecular biology
  5. MicroRNA-32-5p promotes the proliferation and metastasis of gastric cancer cells.2025Scientific reports免费全文
  6. Efficacy of quadratus lumborum block type 3 on postoperative cell-mediated immunity and analgesia for laparoscopic radical gastrectomy: a prospective randomized controlled trial.2025Surgical endoscopyRCT
  7. The Dual-Response-Single-Amplification Fluorescent Nanomachine for Tumor Imaging and Gastric Cancer Diagnosis.2023ACS nano
  8. DSC2 suppresses the growth of gastric cancer through the inhibition of nuclear translocation of γ-catenin and PTEN/PI3K/AKT signaling pathway.2023Aging免费全文
  9. Long Noncoding RNA Regulator of Reprogramming Regulates Cell Growth, Metastasis, and Cisplatin Resistance in Gastric Cancer via miR-519d-3p/HMGA2 Axis.2023Cancer biotherapy & radiopharmaceuticals
  10. GLIS3, a novel prognostic indicator of gastric adenocarcinoma, contributes to the malignant biological behaviors of tumor cells via modulating TGF-β1/TGFβR1/Smad1/5 signaling pathway.2023Cytokine
  11. Ubiquitous mitochondrial creatine kinase promotes the progression of gastric cancer through a JNK-MAPK/JUN/HK2 axis regulated glycolysis.2023Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association免费全文
  12. Regulation of the Hippo/YAP axis by CXCR7 in the tumorigenesis of gastric cancer.2023Journal of experimental & clinical cancer research : CR免费全文
  13. Gastric bacteria as potential biomarkers for the diagnosis of atrophic gastritis.2023Molecular biology reports
  14. Correlation of Claudin18.2 expression with clinicopathological characteristics and prognosis in gastric cancer.2023Pathology, research and practice
  15. Identification of the ferroptosis-related ceRNA network related to prognosis and tumor immunity for gastric cancer.2022Aging免费全文
  16. Targeting kinesin family member 21B by miR-132-3p represses cell proliferation, migration and invasion in gastric cancer.2022Bioengineered免费全文
  17. Association of microRNA polymorphisms with gastric cancer risk in the North Chinese Han population.2022Journal of cancer research and therapeutics
  18. DUB1 suppresses Hippo signaling by modulating TAZ protein expression in gastric cancer.2022Journal of experimental & clinical cancer research : CR免费全文
  19. OTUB1 suppresses Hippo signaling via modulating YAP protein in gastric cancer.2022Oncogene免费全文
  20. Betulinic acid targets drug-resistant human gastric cancer cells by inducing autophagic cell death, suppresses cell migration and invasion, and modulates the ERK/MEK signaling pathway.2021Acta biochimica Polonica
  21. LncRNA DLEU2 is activated by STAT1 and induces gastric cancer development via targeting miR-23b-3p/NOTCH2 axis and Notch signaling pathway.2021Life sciences
  22. A recombinant adenovirus fiber knob protein sensitizes gastric cancer cells to trastuzumab.2021Panminerva medica
中文论文(未计入)1
  1. [Clinicopathological features and research advances of fundic gland type neoplasms].2023Zhonghua bing li xue za zhi = Chinese journal of pathology
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer正在招募NCT04688801牵头方不分期2020-07 启动
  2. Safety and Efficacy Study for MG-7-DC Vaccine in Gastric Cancer Treatment状态不明NCT04567069牵头方I/II期2020-09 启动
  3. Gut Microbiota and Metabonomics状态不明NCT05205187研究中心2022-02 启动
  4. Multi-center and Multi-modal Deep Learning Study of Gastric Cancer状态不明NCT05001321研究中心2021-07 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 14 篇,占 0.6%。

牵头论文
14
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 4420222023: 4420232024: 0020242025: 442025

济南有 24 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文14
  1. Vitamin B12 as a novel USP3 deubiquitinase inhibitor suppresses cell proliferation and growth in osteosarcoma.2025Biochemical and biophysical research communications
  2. Ziyuglycoside II suppressed the progression of osteosarcoma by coordinating estrogen-related receptor gamma and p53 signaling pathway.2025Chinese journal of natural medicines
  3. UBE2L3 Suppresses Oxidative Stress-regulated Necroptosis to Accelerate Osteosarcoma Progression.2025Recent patents on anti-cancer drug discovery
  4. Interfering with UBE2L3 expression targets regulation of MLKL to promote necroptosis inhibition of growth in osteosarcoma.2025World journal of surgical oncology
  5. Cytotoxic Effects of Castalin Nanoparticles Against Osteosarcoma.2023Applied biochemistry and biotechnology
  6. ADAM19 and TUBB1 Correlate with Tumor Infiltrating Immune Cells and Predicts Prognosis in Osteosarcoma.2023Combinatorial chemistry & high throughput screening
  7. Immune-based prognostic biomarkers associated with metastasis of osteosarcoma.2023General physiology and biophysics
  8. A-to-I RNA editing shows dramatic up-regulation in osteosarcoma and broadly regulates tumor-related genes by altering microRNA target regions.2023Journal of applied genetics
  9. Intercalary frozen autografts for reconstruction of bone defects following meta-/diaphyseal tumor resection at the extremities.2022BMC musculoskeletal disorders
  10. Cost-Efficiency Optimization Serves as a Conserved Mechanism that Promotes Osteosarcoma in Mammals.2022Journal of molecular evolution
  11. An evolutionarily conserved mechanism that amplifies the effect of deleterious mutations in osteosarcoma.2022Molecular genetics and genomics : MGG
  12. Analysis of the function and mechanism of DIRAS1 in osteosarcoma.2022Tissue & cell
  13. CT45A1 promotes the metastasis of osteosarcoma cells in vitro and in vivo through β-catenin.2021Cell death & disease
  14. Bioinformatics integrated analysis to investigate candidate biomarkers and associated metabolites in osteosarcoma.2021Journal of orthopaedic surgery and research
早期论文(2016–2020 年)8
  1. PAXX is a novel target to overcome resistance to doxorubicin and cisplatin in osteosarcoma.2020Biochemical and biophysical research communications
  2. Long non-coding RNA TUSC7 suppresses osteosarcoma by targeting miR-211.2019Bioscience reports
  3. LncRNA LOC730101 promotes osteosarcoma cell survival under energy stress.2018Biochemical and biophysical research communications
  4. miRNA-20a upregulates TAK1 and increases proliferation in osteosarcoma cells.2018Future oncology (London, England)
  5. MiRNA-221 from tissue may predict the prognosis of patients with osteosarcoma.2018Medicine
  6. Expression and significance of calreticulin in human osteosarcoma.2017Cancer biomarkers : section A of Disease markers
  7. shRNA-mediated silencing of hTERT suppresses proliferation and promotes apoptosis in osteosarcoma cells.2017Cancer gene therapy
  8. High expression levels of Cyr61 and VEGF are associated with poor prognosis in osteosarcoma.2017Pathology, research and practice

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.09%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

济南有 9 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 7 篇,占 0.4%。

牵头论文
7
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 2220232024: 2220242025: 112025

济南有 7 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的多发性骨髓瘤开放试验。

这些数字背后的记录
研究主题联合用药诊断、微小残留病与危险分层肾脏与骨骼并发症
论文中的科室病理/检验科

这些论文过半是实验室或动物研究。

打开 PubMed 检索ClinicalTrials.gov

血液疾病

再生障碍性贫血

Aplastic anaemia

2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.5%。

牵头论文
2
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

济南有 6 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的再生障碍性贫血开放试验。

这些数字背后的记录
牵头的论文2
  1. Annexin A1: a key regulator of T cell function and bone marrow adiposity in aplastic anaemia.2024The Journal of physiology
  2. Irisin protected hemopoietic stem cells and improved outcome of severe bone marrow failure.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Severe Aplastic Anemia状态不明NCT01182662牵头方(推断)II期2010-08 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

视神经脊髓炎谱系疾病

Neuromyelitis optica spectrum disorder

2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.4%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

济南有 3 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的视神经脊髓炎谱系疾病开放试验。

这些数字背后的记录
研究主题抗体与诊断预防复发影像
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.4%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

济南有 4 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的重症肌无力开放试验。

这些数字背后的记录
研究主题胸腺与胸腺切除抗体与诊断
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.3%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 1120242025: 002025

济南有 9 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

济南有 4 家医院列在杜氏肌营养不良下全国有 116 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录
论文中的科室病理/检验科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

济南有 12 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
论文中的科室病理/检验科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年没有牵头原发性胆汁性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

济南有 7 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Prognostic Value of Noninvasive Fibrosis Scores in Primary Biliary Cholangitis.2019Journal of the College of Physicians and Surgeons--Pakistan : JCPSP

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

山东大学第二医院

Second Hospital of Shandong University

济南

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Qilu Hospital and The Second Hospital; Second Hospital of ShanDong University; Shandong University Second Hospital; SHSU

提出更正下载数据